A weekly print online publication - marketing engine: interviews and news - publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets), Canadian (TSX & TSX-V) and International stock exchanges.

CEOCFO-Members Login

March 12, 2010 Issue

The Most Powerful Name In Corporate News and Information

Energy | Energy-TechEnergy-Infrastructure | Oil & Gas | Jr. Oil & Gas | Natural-Gas | Clean Energy | Renewable-EnergyGreen | Uranium

Precious-Metals | ResourcesMiningMetals | Gold | Capital Goods | Industrial-Goods | Product-DevelopmentWaste-Management 

Healthcare | Biotechnology | Drug-Development | Pharma | Natural-HealthMedical-Device | Medical-Tech | Medical-Instruments | Wellness

Bank |  Financial | Business-Banks |  Community Banks |  Commercial-Bank   | Commercial Banks | Specialty-FinanceBank-Analyst

Regional-Banks | Regional Bank Analyst Mid-Atlantic | Pacific-Bank | Business-Development | REIT Video-Conference | Telepresence

Clean Technology | Technology | Security | Authentication Telecommunications | Semiconductor | Communications | Retail

CURRENT ISSUE  |  INDEX  |  CONTACT  |  FINANCIALS |  SERVICES  | HOME PAGE

Newsflash

Provectus Pharmaceuticals Executes Purchase Agreements for Approximately $5.3 Million Private Placement  - March 9, 2010

Dr. Sanjiv Agarwala to Present Update on Provectus' PV-10  - March 8, 2010

Beacon Enterprise Solutions Announces Two New Engagements with Consumer Companies - March 8, 2010

Vical to Present at Upcoming Investor Conferences - March 1, 2010

California United Bank Announces Positive Fourth Quarter
Performance and Strong 2009 Results - February 28, 2010


Fifth Street Finance Corp. Promotes Bernard D. Berman to President and Announces New Board Member - February 25, 2010

Fifth Street Finance Corp. Receives Long Term Financing Commitment of Up to $150 Million - February 25, 2010

Brandywine Realty Trust Announces Fourth Quarter and Full Year 2009 Earnings - February 24, 2010

Publication of Vical's H5N1 Results Paves the Way for H1N1 Clinical Trial - February 24, 2010

AMERICAN NATIONAL BANKSHARES INC. (VA) ANNOUNCES SHELF REGISTRATION - February 19, 2010

AMERICAN NATIONAL BANKSHARES INC. (VA) ANNOUNCES FIRST QUARTER 2010 CASH DIVIDEND - February 17, 2010

Vical Reports 2009 Financial Results and Progress in Key Development Programs - February 11, 2010

Fifth Street Finance Corp. Announces Quarter Ended December 31, 2009 Financial Results - February 9, 2010

Brandywine Realty Trust Executes 641,433 Square Feet of Leasing in Fourth Quarter 2009 - February 8, 2010


MoreNews

Current Issue
All rights reserved - ceocfointerviews.com

  Walter Banks, Publisher, Christy Rivers, Editor-In-Chief, Charlie Diaz, Associate Publisher & Marketing Director, Lynn Fosse, Senior Editor, Margaret M. Arraiz, Editor, Mike Ponikiewicz, Director of Production and website Publishing.

To view Interviews: highlight & left click on the company name!

March 12, 2010
Healthcare, Technology & Resources
 

Healthcare
Drug Manufacturers - Major

Provectus Pharmaceuticals, Inc. (PVCT-OTC: BB)

We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D.





Subscribe-Now!!! 

Subscriber Reviews
All rights reserved - ceocfointerviews.com

Healthcare
Biotechnology

Urigen Pharmaceuticals, Inc. (URGP-OTC: BB)

Actually, the last pharmaceutical innovation for Painful Bladder Syndrome/Interstitial Cystitis was innovated by our scientific founder, which is important to the Urigen story. He developed a drug, which now sells about $175 million that is marketed in the US by a division of Johnson & Johnson, and co-promoted by Bayer Corporation as well. However, it was approved in late 1996.  So since then in those thirteen or fourteen years we haven’t had a new innovation, and that is the standard of care. With that drug, you have to take it three times per day generally for six months, and you can imagine waiting for six months for a response to your pain, which may not come. So that gives you an idea of the opportunity for URG101, which actually works in a matter of minutes during an office visit. So it is truly a paradigm-shifting product potentially and that is what I saw meeting patients in Dr. Parsons’ clinic in 2003 at the University of California San Diego. - Dr. William J. Garner M.D.


Technology
Liquid Phase Desposition

Natcore Technology Inc. (NXT-TSXV)

Precisely what we are doing with the technology is we replacing the vacuum harnesses, which put on the antireflective coating. Every solar cell has to have an anti-reflective coating. Right now it is done by putting in vacuum harnesses at very high temperatures. Our technology puts the same antireflective coating on those particular solar cells at room temperature in a liquid bath. - Charles Provini

Resources
Precious Metals

A25 Gold Producers Corp. (ALQ-Frankfurt)

There are not many gold mines where you are going to get concentrations of up to 310 grams per tonne; that is 9 ounces per tonne. So if you are extracting 9 ounces per tonne and gold is getting close to $1,500 an ounce, that is a lot of money. - Jim Adams


 



wpe8CC.jpg (12410 bytes)

 

 

 

United EcoEnergy Corp.
(UEEC-OTC: BB)

KAT Exploration Inc.
(KATX-OTCPK)

Sofame Technologies Inc.
(SDW-TSXV)

Seamless Corporation
(SMWF-OTC: BB)

Houston Lake Mining Inc.
(HLM-TSXV)

Accuray Incorporated
(ARAY-NASDAQ)

First State Bancorporation
(FSNM-NASDAQ)

Analyst Covering:
First State Bancorporation

American Pacific Corp.
(APEC-NASDAQ)

 

Become A Member!
JoinNow 

Analyst Interviews






































































 

For More Press Releases
Click Here

 


 

No part of this publication may be reproduced in any form, photocopied or retransmitted or stored in a retrieval system without prior written consent publisher of CEOCFOinterviews.com

Contents of this publication are gathered from sources believed to be reliable, but are not warranted by ceocfointerview.com for any particular use or purpose.   CEOCFOinterviews.com does not purchase stock, and the content of this publication may change and may not be deemed as investment advice.

Any company publishing an analyst interview to accompany their CEO interview has paid considerations to CEOCFOinterviews.com.  To support the independence of an analyst interview, CEOCFOinterviews.com does not submit analyst interviews for review or editing prior to publication, but CEOCFOinterviews.com can not ensure the independence of the analyst.  The Analyst Industry Review was not paid for by any company being published and is strictly editorial.



 

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

##########